Results 11 to 20 of about 4,805 (202)

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma [PDF]

New England Journal of Medicine, 2019
Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options.We administered
Ajai Chari, Dan T Vogl, Msce, Maria Gavriatopoulou   +2 more
exaly   +9 more sources

Selinexor: Targeting a novel pathway in multiple myeloma

eJHaem, 2023
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson   +9 more
doaj   +3 more sources

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges [PDF]

Frontiers in Pharmacology
This article aims to review the current application status and research advancements of selinexor in the treatment of acute myeloid leukemia (AML). Selinexor, as the first oral selective inhibitor of nuclear export protein Exportin-1 (XPO1), inhibits the
Ziyu Qie, Li Ma, Jie Tan, Xiaochun Peng, Xiaochun Peng   +4 more
doaj   +2 more sources

An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study [PDF]

Therapeutic Advances in Hematology
Background: Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma.
Annes Elfar, Andrew V. Tran, Joseph Case, Cole Wayant, Griffin K. Hughes, Ryan McIntire, Brooke Gardner, Chase Ladd, Andriana M. Peña, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar   +12 more
doaj   +2 more sources

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells [PDF]

Hematology Reports
Background/Objectives: Aurora kinases (AURKs) are key regulators of mitosis, and their dysregulation contributes to plasma cell disorders, including multiple myeloma (MM) and plasma cell leukemia (PCL). Methods: The expression and prognostic relevance of
Seiichi Okabe, Yuko Tanaka, Shunsuke Otsuki, Mitsuru Moriyama, Seiichiro Yoshizawa, Akihiko Gotoh, Daigo Akahane   +6 more
doaj   +2 more sources

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors [PDF]

Journal of Hematology & Oncology, 2016
Background Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myeloma-targeted ...
Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark Meads, Rachid Baz, Michael Kauffman, Sharon Shacham, Daniel M. Sullivan   +10 more
doaj   +3 more sources

Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study [PDF]

Nature Communications
Exportin-1 (XPO-1) is related to drug resistance and poor prognosis in solid tumors. Selinexor, an XPO-1 inhibitor, has shown preclinical and clinical activity in sarcomas.
Javier Martin-Broto, Antonio Casado, Gloria Marquina, Andres Redondo, Javier Martinez-Trufero, Claudia Valverde, Antonio Gutierrez, Daniel Bernabeu, Luis Ortega, Jose Merino, Rafael Ramos, Patricio Ledesma, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi   +14 more
doaj   +2 more sources

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Journal of Hematology and Oncology, 2018
Background Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well ...
Lucy A Godley, Wendy Stock, Hongtao Liu
exaly   +3 more sources

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma [PDF]

Cancer Reports
Background Multiple myeloma (MM) is a blood cancer marked by the abnormal clonal growth of plasma cells. Hypoxia plays a critical role in the progression and treatment resistance of MM. Aims This study investigates the expression of B‐cell/CLL lymphoma 2
Seiichi Okabe, Yuya Arai, Yuko Tanaka, Akihiko Gotoh   +3 more
doaj   +2 more sources

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition [PDF]

Journal of Translational Medicine
Background Acute myeloid leukemia (AML) remains a therapeutic challenge due to drug resistance and relapse. Selinexor, an XPO1 inhibitor, shows limited efficacy as monotherapy, necessitating combination strategies. JQ1, a BET inhibitor targeting MYC, may
Pei-Hong Wang, Chu-Hong Hu, Jia-Qi Fan, Jia-Jun He, Ting-Fen Deng, Yan-Li Xu, Yu-Jun Dai, Shun-Qing Wang   +7 more
doaj   +2 more sources